Raise the value of benefits
Keep employees healthy and productive

The effectiveness of most medications depends upon genetic factors. Pillcheck pharmacogenetics (PGx) tests for these genetic factors and helps individuals get medication therapy optimized to their DNA for a wide range of conditions.

Matching medications to DNA leads to 30% fewer side effects.

Benefits for employees

Employees and family members get the right medication at the right dose to help them feel better, sooner. Reduces time away from work due to illness and doctor visits.

Benefits for plans

Plan sponsors avoid the costs of covering ineffective, sometimes harmful prescriptions, and lost productivity until the right treatment is found.

How much will you save with Pillcheck?

Plan members:

Increased productivity


Fixed fee discount


Combined savings


More detail

This is an estimated cost savings over 24 months based on productivity gains for individuals who get their medications optimized with Pillcheck.


  • 1 in 10 employees deal with mental health issues, 1 in 20 struggle with chronic pain, 1 in 12 have heart disease, 1 in 6 are impacted by GERD.

  • Average annual wage of $65,000

  • Cost for Pillcheck PGx is accounted for based on fixed monthly fee pricing over 24 months and includes a customized enrollment and communication program.

The Pillcheck difference

When it comes to genetic testing, we’ve done the research so you don’t have to. Pillcheck is an easy and accurate DNA testing service that you can offer your plan members.


Medication passport for life

  • Pillcheck reports are easy to use and provide immediate answers to medication questions helping employees stay healthy now...and in the future because our DNA doesn’t change
  • New medications are added regularly, according to expanding clinical guidelines

Pharmacist review

  • Includes medication review and personalized action plan by an expert clinical pharmacist
  • Pharmacists are available online or by phone for consultations with doctors or patients

Comprehensive for diverse populations

  • Pillcheck analysis aligns individuals’ genetics with the most commonly prescribed medications
  • Covers drugs for cardiac care, gastrointestinal issues, pain management, oncology, mental health and many other treatment areas
  • DNA analysis optimized to ensure accurate results for multi-ethnic population

Easy to implement

  • Fully digital service for the enterprise and its plan members
  • Seamless implementation program
  • Customized enrollment and communication support
  • Flexible pricing options

A competitive edge for advisors and plan sponsors

Private plan members interested in PGx

Plan sponsors willing to provide coverage

Sanofi Canada Healthcare Survey, 2019, 2020

Proven results

Pillcheck drives workplace productivity by avoiding ineffective or detrimental treatment.


Improves depression recovery

Outcomes for depression, anxiety and disability were almost two times greater with Pillcheck than without.1


Optimizes multiple prescriptions

Pillcheck identified at least one drug-therapy problem for 78% of people taking three or more medications.2


Reduces duration and frequency of disability claims

People on disability often have a variety of health issues and struggle to find effective treatment. Drug or dose changes were recommended for 51% of Pillcheck users on medical leave.

What our customers are saying

Pillcheck is an eligible medical expense provided by a licensed pharmacist and can be reimbursed through Healthcare Spending Accounts or Extended Health Benefits.

Pillcheck protects privacy

  • Test samples destroyed after reports are completed
  • Privacy by design architecture ensures genetic data is not linked to personal information
  • Personal health and genetic data is never shared with insurance or employer
  • Only tests DNA for medication response; does not assess disease risk or diagnosis







Want to schedule a demo or get more information?

    1 Papastergiou J et al, Clin Transl Sci. 2021

    2 Journal of the American Pharmacists Association 2017 Sep-Oct;57(5):624-629

    Skip to content